I agree, I spoke to Dan several times leading up to the reverse split and was very impressed. IMO is qualified CEO to take ADXS' market cap to a level comparable with peers (hundred of millions) given ADXS' clinical trial progress and pipeline and is executed on a strategy to meet that goal. I expect we'll see a licensing partnership finalized before year-end either with Fushion Vax of another company. As far as Orphan designation for cervical and head & neck goes, I agree with James in that the FDA is still deciding. They haven't said no yet - if they had, they would have already posted the anal cancer designation (which they granted) on their website. I think they are waiting to post all three decisions at the same time. If it were a clear-cut no on cervical and head & neck cancer, then we would already know. The fact it's taking this long could be positive if they are weighing data they need to confirm orphan designation (of course, it be the opposite, hope not). One thing I wonder if ADXS has considered putting the HPV vaccine up for FDA break-through designation. I don't know the qualifications with this designation, but considered ADXS' Phase II India cervical cancer survival matched or exceeded all previous drug trials for late stage cervical cancer, I would think break-through status is a possibility since these patients have few other options available.
News 
Market Data 
Discover 
AI
